In August 2017, TAP partnered with Ryvu Therapeutics (formerly known as Selvita) to support "A Phase 1b Study of RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome."
Ryvu Therapeutics is a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology. RVU120 is a highly selective first-in-class CDK8/CDK19 inhibitor that was discovered with the Ryvu Therapeutics discovery engine platform. CDK8 plays a unique and critical role in gene regulation and is implicated in the development of numerous hematological malignancies and solid tumors.
Ryvu is currently enrolling a Phase 2 clinical trial of RVU120 in combination with venetoclax for patients with relapsed/refractory AML (RIVER-81, NCT06191263)
For more information about Ryvu, visit ryvu.com.
Recent News
- June 11, 2026 - presented clinical data and program update on romaciclib at the EHA Congress 2026
- December 7, 2025 - presented clinical data from RIVER-81 and POTAMI-61 studies of Romaciclib (RVU120) at 2025 ASH Annual Meeting
- December 4, 2024 - announced dosing of the first patient in POTAMI-61 Phase II Study of RVU120 for treatment of patients with myelofibrosis
- September 19, 2024 - announced that the first patient has been dosed in the REMARK study, a Phase II clinical trial investigating RVU120 as a monotherapy for the treatment of patients with LR-MDS.
- January 31, 2024 - announced that the first patient has been dosed with the study drugs in a Phase 2 clinical trial investigating RVU120 in combination with venetoclax for the treatment of patients with relapsed/refractory acute myeloid leukemia (r/r AML) – the RIVER-81 study
- March 15, 2023 - named the Warsaw Stock Exchange Company of the Year in a competition organized by the largest business daily in Poland - Puls Biznesu.
- December 22, 2022 – announced completion of its public offering of Series J common shares. As a result, Ryvu has obtained gross proceeds of PLN 250.3 million ($57M USD) from institutional and individual investors as well as BioNTech and the Therapy Acceleration Program (TAP).
- December 11, 2022 – announced new data demonstrating clinical and preclinical activity of its selective CDK8/19 inhibitor RVU120 at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, which is being held on December 10 –13, 2022, in New Orleans, Louisiana.
- May 12, 2022 - announced that the data from the Phase 1b dose-escalation study of RVU120 (SEL120) in patients with AML or high-risk myelodysplastic syndromes (HR-MDS) will be presented at the EHA 2022 Hybrid Congress, June 9-17 in Vienna, Austria.